Minakem Header W48

Minakem Header W48

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

Inversago Pharma

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Inversago Pharma Presents Data on INV-202 in Diabetic Nephropathy at the ERA 2022 Congress

Details:

INV-202 is a small molecule CB1 inverse agonist / antagonist being developed by Inversago for the potential treatment of several metabolic conditions, including Diabetic Nephropathy.

Lead Product(s): INV-202

Therapeutic Area: Nephrology Product Name: INV-202

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 19, 2022

ASK
US

Upload
your Pipeline Activity

Inversago Pharma

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Inversago Pharma Announces Dosing of First Participant With Metabolic Syndrome in Phase 1B Clinical Trial

Details:

INV-202, first-in-class, peripheral CB1 inhibitor, demonstrated efficacy in addressing multiple pathways involved in renal injury also have shown clinical improvements in lipids, weight loss and glucose.

Lead Product(s): INV-202

Therapeutic Area: Nephrology Product Name: INV-202

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 15, 2022

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY